Clinical Trial Update: A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase I/II study evaluating VORAXAZE for central nervous system lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Voraxaze (glucarpidase)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: CNS Lymphoma | Phase 1, Phase 2 | Status: COMPLETED